Transmissibility of mouse AApoAII amyloid fibrils: Inactivation by physical and chemical methods

FASEB Journal

Volumn 20, Issue 7, 2006, Pages

  Zhang, Huanyu ^a   Sawashita, Jinko ^a   Fu, Xiaoying ^a   Korenaga, Tatsumi ^a   Yan, Jingmin ^a   Mori, Masayuki ^a   Higuchi, Keiichi ^a  

^a SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Amyloidosis; Disruption; Organic compounds

Indexed keywords

AMYLOID; CEFALEXIN; CHLORAMPHENICOL; ERYTHROMYCIN; FORMALDEHYDE; FORMIC ACID; GUANIDINE; LINCOMYCIN; NORDIHYDROGUAIARETIC ACID; ORGANIC COMPOUND; PENICILLIN G; POLYMYXIN B; PROTEIN AAPOA2; PROTEINASE K; QUERCETIN; RESVERATROL; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE; THIOFLAVINE; UREA; APOLIPOPROTEIN A2; FORMIC ACID DERIVATIVE;

AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DOSE RESPONSE; DRUG MECHANISM; ELECTRON MICROSCOPY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUSCLE FIBRIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STRUCTURE; ANIMAL; CHEMISTRY; DRUG EFFECT; METABOLISM; MOUSE MUTANT; PROTEIN DENATURATION; PROTEIN QUATERNARY STRUCTURE;

AMYLOID; AMYLOIDOSIS; ANIMALS; APOLIPOPROTEIN A-II; FORMIC ACIDS; GUANIDINE; MICE; MICE, MUTANT STRAINS; PROTEIN DENATURATION; PROTEIN STRUCTURE, QUATERNARY;

EID: 33845648426     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.05-4890fje     Document Type: Article

References (55)

1. Westermark, P. (1998) The pathogenesis of amyloidosis: understanding general principles. Am. J. Pathol. 152, 1125-1127
2. Westermark, P., Benson, M. D., Buxbaum, J. N., Cohen, A. S., Frangione, B., Ikeda, S., Masters, C. L., Merlini, G., Saraiva, M. J., and Sipe, J. D. (2002) Amyloid fibril protein nomenclature - 2002. Amyloid 9, 197-200
3. Booth, D. R., Sunde, M., Bellotti, V., Robinson, C. V., Hutchinson, W. L., Fraser, P. E., Hawkins, P. N., Dobson, C. M., Radford, S. E., Blake, C. C., and Pepys, M. B. (1997) Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 385, 787-793
4. Glenner, G. G. (1980) Amyloid deposits and amyloidosis. The beta-fibrilloses. N. Engl. J. Med. 302, 1283-1292
5. Higuchi, K., Yonezu, T., Kogishi, K., Matsumura, A., Takeshita, S., Higuchi, K., Kohno, A., Matsushita, M., Hosokawa, M., and Takeda, T. (1986) Purification and characterization of a senile amyloid-related antigenic substance (apoSASSAM) from mouse serum. apoSASSAM is an apoA-II apolipoprotein of mouse high density lipoproteins. J. Biol. Chem. 261, 12834-12840
6. Benson, M. D., Liepnieks, J. J., Yazaki, M., Yamashita, T., Hamidi Asl, K., Guenther, B., and Kluve-Beckerman, B. (2001) A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene. Genomics 72, 272-277
7. Yonezu, T., Higuchi, K., Tsunasawa, S., Takagi, S., Sakiyama, F., and Takeda, T. (1986) High homology is present in the primary structures between murine senile amyloid protein (ASSAM) and human apolipoprotein A-II. FEBS Lett. 203, 149-152
8. Higuchi, K., Kitado, H., Kitagawa, K., Kogishi, K., Naiki, H., and Takeda, T. (1993) Development of congenic strains of mice carrying amyloidogenic apolipoprotein A-II (Apoa2c). Apoa2c reduces the plasma level and the size of high density lipoprotein. FEBS Lett. 317, 207-210
9. Higuchi, K., Naiki, H., Kitagawa, K., Kitado, H., Kogishi, K., Matsushita, T., and Takeda, T. (1995) Apolipoprotein A-II gene and development of amyloidosis and senescence in a congenic strain of mice carrying amyloidogenic ApoA-II. Lab. Invest. 72, 75-82
10. Jarrett, J. T., and Lansbury, P. T. Jr. (1993) Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73, 1055-1058
11. Bessen, R. A., Kocisko, D. A., Raymond, G. J., Nandan, S., Lansbury, P. T., and Caughey, B. (1995) Non-genetic propagation of strain-specific properties of scrapie prion protein. Nature 375, 698-700
12. Higuchi, K., Kogishi, K., Wang, J., Chen, X., Chiba, T., Matsushita, T., Hoshii, Y., Kawano, H., Ishihara, T., Yokota, T., and Hosokawa, M. (1998) Fibrilization in mouse senile amyloidosis is fibril conformation-dependent. Lab. Invest. 78, 1535-1542
13. Caughey, B. (2000) Transmissible spongiform encephalopathies, amyloidoses and yeast prions: common threads? Nat. Med. 6, 751-754
14. Wickner, R. B., Edskes, H. K., Maddelein, M. L., Taylor, K. L., Moriyama, H. (1999) Prion of yeast and fungi. Proteins as genetic material. J. Biol. Chem. 274, 555-558
15. Chesebro, B. (1998) BSE and prions: uncertainties about the agent. Science 279, 42-43
16. Xing, Y., Nakamura, A., Chiba, T., Kogishi, K., Matsushita, T., Fu, L., Guo, Z., Hosokawa, M., Mori, M., and Higuchi, K. (2001) Transmission of mouse senile amyloidosis. Lab. Invest. 81, 493-499
17. Fu, X., Korenaga, T., Fu, L., Xing, Y., Guo, Z., Matsushita, T., Hosokawa, M., Naiki, H., Baba, S., Kawata, Y., Ikeda, S., Ishihara, T., Mori, M., and Higuchi, K. (2004) Induction of AApoAII amyloidosis by various heterogeneous amyloid fibrils. FEBS Lett. 563, 179-184
18. Cui, D., Kawano, H., Takahashi, M., Hoshii, Y., Setoguchi, M., Gondo, T., and Ishihara, T. (2002) Acceleration of murine AA amyloidosis by oral administration of amyloid fibrils extracted from different species. Pathol. Int. 52, 40-45
19. Lundmark, K., Westermark, G. T., Nystrom, S., Murphy, C. L., Solomon, A., and Westermark, P. (2002) Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc. Natl. Acad. Sci. USA 99, 6979-6984
20. Baker, H. F., Ridley, R. M., Duchen, L. W., Crow, T. J., and Bruton, C. J. (1994) Induction of beta (A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate. Comparison with transmission of spongiform encephalopathy. Mol. Neurobiol. 8, 25-39
21. Sigurdsson, E. M., Wisniewski, T., Frangione, B. (2002) Infectivity of amyloid diseases. Trends. Mol. Med. 8, 411-413
22. Fichet, G., Comoy, E., Duval, C., Antloga, K., Dehen, C., Charbonnier, A., McDonnell, G., Brown, P., Lasmezas, C. I., and Deslys, J. P. (2004) Novel methods for disinfection of prion-contaminated medical devices. Lancet. 364, 521-526
23. McDonnell, G., and Burke, P. (2003) The challenge of prion decontamination. Clin. Infect. Dis. 36, 1152-1154
24. Merlini, G., Ascari, E., Amboldi, N., Bellotti, V., Arbustini, E., Perfetti, V., Ferrari, M., Zorzoli, I., Marinone, M. G., Garini, P., Diegoli, M., Trizio, D., and Ballinari, D. (1995) Interaction of the anthracycline 4′-indo-4′-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc. Natl. Acad. Sci. USA 92, 2959-2963
25. Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., Mclendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., and Golde, T. E. (2003) NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest. 112, 440-449
26. May, B. C., Fafarman, A. T., Hong, S. B., Rogers, M., Deady, L. W., Prusiner, S. B., and Cohen, F. E. (2003) Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. Proc. Natl. Acad. Sci. USA 100, 3416-3421
27. Forloni, G., Iussich, S., Awan, T., Colombo, L., Angeretti, N., Girola, L., Bertani, I., Poli, G., Caramelli, M., Grazia Bruzzone, M., Farina, L., Limido, L., Rossi, G., Giaccone, G., Ironside, J. W., Bugiani, O., Salmona, M., and Tagliavini, F. (2002) Tetracyclines affect prion infectivity. Proc. Natl. Acad. Sci. USA 99, 10,849-10,854
28. Tomiyama, T., Shoji, A., Kataoka, K., Suwa, Y., Asano, S., Kaneko, H., and Endo, N. (1996) Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. J. Biol. Chem. 271, 6839-6844
29. Ono, K., Hasegawa, K., Yoshiike, Y., Takashima, A., Yamada, M., and Naiki, H. (2002) Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer's beta-amyloid fibrils in vitro. J. Neurochem. 81, 434-440
30. Pras, M., Zucker-Franklin, D., Rimon, A., and Franklin, E. C. (1969) physical, chemical, and ultrastructural studies of water-soluble human amyloid fibrils. Comparative analyses of nine amyloid preparations. J. Exp. Med. 130, 777-796
31. Xing, Y., Nakamura, A., Korenaga, T., Guo, Z., Yao, J., Fu, X., Matsushita, T., Kogishi, K., Hosokawa, M., Kametani, F., Mori, M., and Higuchi, K. (2002) Induction of protein conformational change in mouse senile amyloidosis. J. Biol. Chem. 277, 33,164-33,169
32. Chiba, T., Kogishi, K., Wang, J., Xia, C., Matsushita, T., Miyazaki, J., Saito, I., Hosokawa, M., and Higuchi, K. (1999) Mouse senile amyloid deposition is suppressed by adenovirus-mediated overexpression of amyloid-resistant apolipoprotein A-II. Am. J. Pathol. 155, 1319-1326
33. Klunk, W. E., and Pettegrew, J. W. (1990) Alzheimer's beta-amyloid protein is covalently modified when dissolved in formic acid. J. Neurochem. 54, 2050-2056
34. Safar, J., Roller, P. P., Gajdusek, D. C., and Gibbs, C. J. Jr. (1993) Thermal stability and conformational transitions of scrapie amyloid (prion) protein correlate with infectivity. Protein. Sci. 2, 2206-2216
35. Brown, P., Rohwer, R. G., and Gajdusek, D. C. (1984) Sodium hydroxide decontamination of Creutzfeldt-Jakob disease virus. N. Engl. J. Med. 310, 727
36. Safar, J., Roller, P. P., Gajdusek, D. C., and Gibbs, C. J. Jr. (1993) Conformational transitions, dissociation and unfolding of scrapie amyloid (prion) protein. J. Biol. Chem. 268, 20276-20284
37. Fischer, M. B., Roeckl, C., Parizek, P., Schwarz, H. P., and Aguzzi, A. (2000) Binding of disease-associated prion protein to plasminogen. Nature 408, 479-483
38. Botelho, M. G., Gralle, M., Oliveira, C. L., Torriani, I., and Ferreira, S. T. (2003) Folding and stability of the extracellular domain of the human amyloid precursor protein. J. Biol. Chem. 278, 34,259-34,267
39. Brown, P., Rohwer, R. G., Green, E. M., and Gajdusek, D. C. (1982) Effect of chemicals, heat, and histopathologic processing on high-infectivity hamster-adapted scrapie virus. J. Infect. Dis. 145, 683-687
40. Southwick, P. C., Yamagata, S. K., Echols, C. L. Jr., Higson, G. J., Neynaber, S. A., Parson, R. E., and Munroe, W. A. (1996) Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. J. Neurochem. 66, 259-265
41. Vanderstichele, H., Van Kerschaver, E., Hesse, C., Davidsson, P., Buyse, M. A., Andreasen, N., Minthon, L., Wallin, A., Blennow, K., and Vanmechelen, E. (2000) Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 7, 245-258
42. Deleault, N. R., Lucassen, R. W., and Supattapone, S. (2003) RNA molecules stimulate prion protein conversion. Nature 425, 717-720
43. Zobeley, E., Flechsig, E., Cozzio, A., Enari, M., and Weissmann, C. (1999) Infectivity of scrapie prions bound to a stainless steel surface. Mol. Med. 5, 240-243
44. Silveira, J. R., Raymond, G. J., Hughson, A. G., Race, R. E., Sim, V. L., Hayes, S. F., Caughey, B. (2005) The most infectious prion protein particles. Nature 437, 257-261
45. Bitan, G., Fradinger, E. A., Spring, S. M., and Teplow, D. B. (2005) Neurotoxic protein oligomers-what you see is not always what you get. Amyloid 12, 88-95
46. Stefani, M., and Dobson, C. M. (2003) Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 81, 678-699
47. Zerovnik, E. (2002) Amyloid-fibril formation. Proposed mechanisms and relevance to conformational disease. Eur. J. Biochem. 269, 3362-3371
48. Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C. M., and Stefani, M. (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416, 507-511
49. Ban, T., Hamada, D., Hasegawa, K., Naiki, H., and Goto, Y. (2003) Direct observation of amyloid fibril growth monitored by thioflavin T fluorescence. J. Biol. Chem. 278, 16462-16465
50. Prusiner, S. B. (1998) Prions. Proc. Natl. Acad. Sci. USA 95, 13,363-13,383
51. Forloni, G., Colombo, L., Girola, L., Tagliavini, F., and Salmona, M. (2001) Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett. 487, 404-407
52. Cardoso, I., Merlini, G., and Saraiva, M. J. (2003) 4′-iodo- 4′-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB J. 17, 803-809
53. Naiki, H., Hasegawa, K., Yamaguchi, I., Nakamura, H., Geiyo, F., and Nakakuki, K. (1998) Apolipoprotein E and antioxidants have different mechanisms of inhibiting Alzheimer'sedimentary coeffcient beta-amyloid fibril formation in vitro. Biochemistry 37, 17,882-17,889
54. Moss, M. A., Varvel, N. H., Nichols, M. R., Reed, D. K., and Rosenberry, T. L. (2004) Nordihydroguaiaretic acid does not disaggregate beta-amyloid (1-40) protofibrils but does inhibit growth arising from direct protofibril association. Mol. Pharmacol. 66, 592-600
55. Ono, K., Yoshiike, Y., Takashima, A., Hasegawa, K., Naiki, H., and Yamada, M. (2003) Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J. Neurochem. 87, 172-181